Arcus Biosciences, Inc. (RCUS)

Market Cap	3.20B +280.3%
Revenue (ttm)	247.00M -4.3%
Net Income	-353.00M
EPS	-3.29
Shares Out	125.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	731,360
Open	25.48
Previous Close	25.13
Day's Range	24.58 - 25.91
52-Week Range	7.06 - 28.72
Beta	0.86
Analysts	Buy
Price Target	31.90 (+25.1%)
Earnings Date	May 5, 2026

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 15, 2018
• Employees: 601
• Stock Exchange: NYSE
• Ticker Symbol: RCUS
• Website: https://arcusbio.com

Financial Performance

In 2025, Arcus Biosciences's revenue was $247.00 million, a decrease of -4.26% compared to the previous year's $258.00 million. Losses were -$353.00 million, 24.7% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price target is $31.9, which is an increase of 25.10% from the latest price.

Price Target

$31.9

(25.10% upside)

Analyst Consensus: Buy